CXCR2 and melanoma: Using the RET transgenic mouse melanoma model, which resembles melanoma development in patients [29,30], we found a significant reduction of PMN-MDSC in the tumor microenvironment that was associated with a survival benefit upon the therapy with the CXCR2 inhibitor.